Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab in pre-symptomatic type 1 diabetes
NCT03298542Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing Golimumab with Placebo (2 arms). Primary endpoints: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Up to Week 26, Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Up to Week 52 and 4 more. Started Oct 2017; status: completed.
02
Drugs
golimumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03298542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03298542.